Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms

Xenobiotica

Volumn 28, Issue 4, 1998, Pages 337-348

  Renwick, A B ^a   Mistry, H ^a   Ball, S E ^b   Walters, D G ^a   Kao, J ^b   Lake, B G ^a  

^a BIBRA INTERNATIONAL   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CL 284859; CL 345644; CL 345905; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; MEPHENYTOIN; QUINIDINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; ZALEPLON;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; LIVER METABOLISM; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL;

ACETAMIDES; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; HYPNOTICS AND SEDATIVES; ISOENZYMES; KINETICS; MICROSOMES, LIVER; PYRIMIDINES; RECOMBINANT PROTEINS;

EID: 0031958417     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239452     Document Type: Article

References (27)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
2. BURKE, M. D. and MAYER, R. T., 1974, Ethoxyresorufin : direct fluorimetric assay of microsomal O-dealkylation which is preferentially induced by 3-methycholanthrene. Drug Metabolism and Disposition, 2, 583-588.
3. CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517-526.
4. GIERA, D. D. and VAN LIER, R. B. L., 1991, A convenient method for the determination of hepatic lauric acid ω-oxidation based on solvent partition. Fundamental and Applied Toxicology, 16, 348-355.
5. GONZALEZ, F. J., CRESPI, C. L. and GELBOIN, H. V., 1991, cDNA-expressed human cytochrome P-450s: a new age of molecular toxicology and human risk assessment. Mutation Research, 247, 113-127.
6. HO, P., TRIGGS, E. J., HEAZLEWOOD, V. and BOURNE, D. W. A., 1983, Determination of nitrazepam and temazepam in plasma by high performance liquid chromatography. Therapeutic Drug Monitoring, 5, 303-307.
7. KAWASHIMA, K., HOSOI, K., TAINAKA, H., SUBRAHMANYAM, V. V., NARUKE, T., SHIBA, T., KISHI, I. and WATABE, T., 1998, In vitro metabolism of CL284,846 using subcellular fraction of human liver. Drug Metabolism and Disposition (submitted).
8. KRONBACH, T., 1991, Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods in Enzymology, 206, 509-517.
9. LAKE, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In Biochemical Toxicology : A Practical Approach, edited by K. Snell and B. Mullock (Oxford: IRL), pp. 183-215.
10. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
11. MEIER, U. T., DAYER, P., MALÈ, P. J., KRONBACH, T. and MEYER, U.R., 1985, Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes from poor metabolizers phenotyped in vivo. Clinical Pharmacology and Therapeutics, 38, 488-494.
12. NALINE, E., FLOUVAT, B., ADVENIER, C. and PAYS, M., 1987, Determination of theophylline and its metabolites in plasma and urine by reverse-phase liquid chromatography using an amine modifier. Journal of Chromatography, 419, 177-189.
13. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
14. NEWTON, D. J., WANG, R.W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
15. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
16. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
17. PARKINSON, A., 1996a, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24, 45-57.
18. PARKINSON, A., 1996b, Biotransformation of xenobiotics. In Casarett and Doull's Toxicology : The Basic Science of Poisons, 5th edn, edited by C. D. Klaassen (New York: McGraw Hill), pp. 113-186.
19. PEARCE, R., GREENWAY, D. and PARKINSON, A., 1992, Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes : effects on coumarin, dicumarol, and testosterone oxidation. Archives of Biochemistry and Biophysics, 298, 211-225.
20. PETER, R., BÖCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human cytochrome P-450IIE1. Chemical Research in Toxicology, 3, 566-573.
21. RODRIGUES, A. D., 1994, Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochemical Pharmacology, 48, 197-200.
22. SCHWAB, G. E., RAUCY, J. L. and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-cataly;ced steroid hydroxylations by α-naphthoflavone. Molecular Pharmacology, 33, 493-499.
23. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals : studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
24. SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCKILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Drug Metabolism and Disposition, 255, 27-41.
25. TASSANEEYAKUL, W., BIRKETT, D. J., MCMANUS, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767-1776.
26. UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
27. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453-484.